ZYMEWORKS WKN: A3DSSN ISIN: US98985Y1082 Forum: Aktien User: Summer.76

https://ir.zymeworks.com/news-releases/news-release-details/new-clinical-data-zanidatamab-her2-hr-metastatic-breast-cancer-0

Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium https://www.businesswire.com/news/home/20221214005989/en/Zanidatamab-Clinical-Data-Selected-For-Presentation-At-The-American-Society-Of-Clinical-Oncology-ASCO-Gastrointestinal-Cancers-Symposium ...today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, 2023. ....

⬆️

🎈

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab https://www.businesswire.com/news/home/20221219005219/en/Zymeworks-Announces-Positive-Topline-Data-in-the-Pivotal-HERIZON-BTC-01-Trial-of-Zanidatamab • Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC) • Pending receipt of regulatory approvals, zanidatamab has the potential to be the first HER2-targeted therapy for patients with BTC

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-transfer-stock-listing-nasdaq Zymeworks To Transfer Stock Listing To Nasdaq

Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals https://www.businesswire.com/news/home/20221129005175/en/Zymeworks-Announces-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Zanidatamab-License-Agreement-with-Jazz-Pharmaceuticals

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-participation-upcoming-investor-conference-0

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) https://www.businesswire.com/news/home/20221121005239/en/Zymeworks-Announces-Abstract-For-Zanidatamab-In-Late-Line-HER2-Positive-Hormone-Receptor-Positive-HR-Metastatic-Breast-Cancer-At-The-San-Antonio-Breast-Cancer-Symposium-SABCS ...A poster with an updated and expanded data set will be presented at SABCS taking place in San Antonio, Texas and virtually on December 6-9, 2022. ...

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M https://seekingalpha.com/news/3904028-zymeworks-non-gaap-eps-of-0_66-beats-0_31-revenue-of-2_6m-misses-1_95m • Zymeworks press release (NYSE:ZYME): Q3 Non-GAAP EPS of -$0.66 beats by $0.31. • Revenue of $2.6M (-40.9% Y/Y) misses by $1.95M.

https://biv.com/article/2022/11/zymeworks-cuts-q3-losses-us48m-bc-biotech-reincorporates-us

Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results https://www.businesswire.com/news/home/20221108006218/en/Zymeworks-Provides-Corporate-Update-and-Reports-Third-Quarter-2022-Financial-Results

News fehlen, aber das Volumen ist ordentlich heute.